), an international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today announced that it has appointed finance veteran Alexi Papaconstantinou to the Company's Advisory Board. Mr. Papaconstantinou is a capital markets veteran and brings over 20 years of experience in investment banking, equity financing, portfolio management and mergers and acquisitions with a particular focus on high-growth public and private companies. Mr. Papaconstantinou is currently the Co-founder and Managing Partner of Lacerta Partners, a family office backed multi-strategy fund. Prior to Co-founding Lacerta Partners, Mr. Papaconstantinou served as Portfolio Manager/Senior Investment Analyst at a number of well-known hedge funds, including Point72 and Moore Capital Management in London. Earlier in his career, Mr. Papaconstantinou held various positions within the Investment Banking Division at Morgan Stanley in London, where he worked on numerous M&A and capital markets transactions across a broad spectrum of industries including transport, financial institutions, retail, and pharma. Mr. Papaconstantinou received a B.A. in Economics and graduated Magna cum laude from Yale University.